SobreNegócios
AjudaPrivacidadeCondições
ResumoLegal e statusLinha do tempoRedePropriedade e gestãoAcionistasBeneficiário efetivoGeografiaFinançasSaúde financeiraDocumentos
ResumoLegal e statusLinha do tempoRedePropriedade e gestãoAcionistasBeneficiário efetivoGeografiaFinançasSaúde financeiraDocumentos

BIOSCRIPT MIDCO 1 LIMITED

🇬🇧Reino Unido•Private Limited Company (Ltd.)•Ativa

Resumo

País🇬🇧Reino Unido
EstadoAtiva
Número de registro13208513
Fundada17/02/2021
Objeto socialActivities of other holding companies n.e.c.
EndereçoSuite A, Greenway House Larkwood Way, Tytherington Business Park, Macclesfield, SK10 2XR
Declaração de confirmaçãoPróximo vencimento: 06/02/2027; Última elaboração: —

Legal e status

Forma legalPrivate Limited Company (Ltd.)
EstadoAtiva
Data de registro17/02/2021
Autoridade registralCompanies House
Capital registrado—

Fonte: UK Companies House · Última atualização: 02/12/2025

Linha do tempo (24 eventos)

03/04/2026

Endereço atualizado

Suite A, Greenway House Larkwood Way, Tytherington Business Park

27/06/2025

Contas anuais apresentadas

Full accounts made up to 30 September 2024

Ver ficheiro em Documentos

17/02/2021

Nomeação Trevor Stokes (pessoa)

Nomeado como Director

Rede

Este diagrama tem muitas conexões. para uma melhor experiência.
Press enter or space to select a node. You can then use the arrow keys to move the node around. Press delete to remove it and escape to cancel.
Press enter or space to select an edge. You can then press delete to remove it or escape to cancel.
Profundidade da rede

Propriedade e gestão

Persons with significant control

Bioscript Holdings Limited

75–100% shares · 75–100% voting rights · Right to appoint directors

Nomeado em: 17/02/2021

87.5%

Officers & directors

James Maxwell

Director

Nomeado em: 15/02/2024

—
Gabrielle Alison Silver

Director

Nomeado em: 02/05/2023

—
Daniel Chaffer

Director

Nomeado em: 07/07/2021 · Demitido em: 14/07/2023

—
Andrew John Medley

Director

Nomeado em: 07/07/2021 · Demitido em: 19/04/2024

—

Mostrando 1–5 de 7

1 / 2

Linha do tempo de propriedade (1 alterações)

17/02/2021

Nomeação Bioscript Holdings Limited (empresa)

owns or controls

Acionistas

NomeParticipaçãoVotoDesde
▓▓▓▓▓▓▓▓▓▓▓▓
█.██%
██%
█.█%
▓▓▓▓▓▓▓▓▓▓▓
██%
█.█%
██.██%
▓▓▓▓▓▓▓▓▓▓▓▓▓
█.█%
██.██%
██.█%
▓▓▓▓▓▓▓▓▓▓
██.██%
██.█%
█.██%
▓▓▓▓▓▓▓▓▓▓▓▓
██.█%
█.██%
██%
▓▓▓▓▓▓▓▓▓▓▓
█.██%
██%
█.█%
▓▓▓▓▓▓▓▓▓▓▓▓▓
██%
█.█%
██.██%
▓▓▓▓▓▓▓▓▓▓
█.█%
██.██%
██.█%

Beneficiário efetivo

NomeParticipaçãoPaísDesde
▓▓▓▓▓▓▓▓▓▓▓▓
█.██%
██%
█.█%
▓▓▓▓▓▓▓▓▓▓▓
██%
█.█%
██.██%
▓▓▓▓▓▓▓▓▓▓▓▓▓
█.█%
██.██%
██.█%
▓▓▓▓▓▓▓▓▓▓
██.██%
██.█%
█.██%
▓▓▓▓▓▓▓▓▓▓▓▓
██.█%
█.██%
██%
▓▓▓▓▓▓▓▓▓▓▓
█.██%
██%
█.█%
▓▓▓▓▓▓▓▓▓▓▓▓▓
██%
█.█%
██.██%
▓▓▓▓▓▓▓▓▓▓
█.█%
██.██%
██.█%

Geografia

Sede

Suite A

Greenway House Larkwood Way, Tytherington Business Park

Macclesfield

SK10 2XR

Finanças

Indicadores das demonstrações anuais.

Converter para

2021

Lucro / (prejuízo): £-190.0K

Indicadores

Lucro / (prejuízo)

2021£-190.017
2022£-190.017
2023£87.003
2024£141.779

Outras receitas

2021£1.628.440
2022£1.628.440
2023£3.652.957
2024£3.913.386

Ativo total

2021£2.998.849
2022£2.998.849
2023£7.099.235
2024£6.090.534

Net Assets Liabilities

2021£2.998.849
2022£2.998.849
2023£7.099.235
2024£6.090.534

Equity

2021£2.998.849
2022£2.998.849
2023£7.099.235
2024£6.090.534

Current Assets

2021£29.849.580
2022£29.849.580
2023£37.459.297
2024£44.307.269

Net Current Assets Liabilities

2021£29.217.422
2022£29.217.422
2023£34.227.342
2024£37.089.265

Total Assets Less Current Liabilities

2021£32.041.480
2022£32.041.480
2023£41.384.070
2024£44.261.352

Debtors

2021£29.849.580
2022£29.849.580
2023£37.459.297
2024£44.307.269

Creditors

2021£29.042.631
2022£29.042.631
2023£34.284.835
2024£38.170.818

Other Creditors

2021£166.941
2022£166.941
2023£0
2024£37.600

Amounts Owed To Group Undertakings

2021—
2022£0
2023£332.292
2024£332.393

Investments Fixed Assets

2021£2.824.058
2022£2.824.058
2023£7.156.728
2024£7.172.087

Issue Equity Instruments

2021—
2022£2.824.058
2023£4.185.418
2024£900.000

Number Shares Issued Fully Paid

202196.301
202296.301
2023417.617.629
2024417.617.075

Par Value Share

2021£0
2022£0
2023£0
2024£0

Despesas administrativas

2021£9.761
2022£9.761
2023—
2024—

Accrued Liabilities Deferred Income

2021£317.137
2022£317.137
2023£1.220.889
2024£2.106.872

Amounts Owed By Group Undertakings

2021£29.659.563
2022£29.659.563
2023£37.356.283
2024£44.307.269

Applicable Tax Rate

2021£0
2022£0
2023£0
2024£0

Audit Fees Expenses

2021£2.000
2022£2.000
2023—
2024—

Comprehensive Income Expense

2021—
2022£174.791
2023£-85.032
2024£-1.024.060

Corporation Tax Payable

2021£6.880
2022£6.880
2023£0
2024£38.665

Current Tax For Period

2021£6.880
2022£6.880
2023—
2024—

Deferred Tax Asset Debtors

2021£190.017
2022£190.017
2023£103.014
2024—

Deferred Tax Assets

2021£190.017
2022£190.017
2023£103.014
2024—

Deferred Tax Expense Credit Relating To Changes In Tax Rates Or Laws

2021£-45.604
2022£-45.604
2023£20.881
2024—

Deferred Tax Expense Credit Relating To Origination Reversal Timing Differences

2021£-144.413
2022£-144.413
2023£66.122
2024£103.014

Fixed Assets

2021£2.824.058
2022£2.824.058
2023£7.156.728
2024£7.172.087

Further Item Increase Decrease In Equity Component Total Income Expense Recognised Directly In Equity

2021—
2022—
2023—
2024£15.359

Income Expense Recognised Directly In Equity

2021—
2022£2.824.058
2023£4.185.418
2024£15.359

Increase Decrease In Current Tax From Adjustment For Prior Periods

2021—
2022£0
2023£-6.880
2024£38.765

Increase Decrease In Net Deferred Tax Liability From Amount Recognised In Profit Or Loss

2021£-190.017
2022£-190.017
2023£87.003
2024—

Interest Income From Group Undertakings

2021£1.628.440
2022£1.628.440
2023£3.652.957
2024£3.913.386

Interest Payable Similar Charges Finance Costs

2021£1.627.025
2022£1.627.025
2023£3.657.866
2024£4.795.667

Net Deferred Tax Liability Asset

2021£-190.017
2022£-190.017
2023£-103.014
2024—

Operating Profit Loss

2021£-9.761
2022£-9.761
2023—
2024—

Other Interest Expense

2021£1.627.025
2022£1.627.025
2023£3.657.866
2024£4.795.667

Other Interest Receivable Similar Income Finance Income

2021£1.628.440
2022£1.628.440
2023£3.652.957
2024£3.913.386

Other Remaining Borrowings

2021£28.725.494
2022£28.725.494
2023£4.338.452
2024£3.000.000

Percentage Class Share Held In Subsidiary

2021£1
2022£1
2023£1
2024£1

Profit Loss On Ordinary Activities After Tax

2021£174.791
2022£174.791
2023£-85.032
2024£-1.024.060

Profit Loss On Ordinary Activities Before Tax

2021£-8.346
2022£-8.346
2023£-4.909
2024£-882.281

Tax Expense Credit Applicable Tax Rate

2021£-1.586
2022£-1.586
2023£-933
2024£-220.570

Tax Increase Decrease Arising From Group Relief Tax Reconciliation

2021£-300.669
2022£-300.669
2023£-647.386
2024£-978.347

Tax Increase Decrease From Effect Expenses Not Deductible For Tax Purposes Other Than Goodwill Amortisation Impairment

2021£164.722
2022£164.722
2023£714.441
2024£1.301.931

Tax Increase Decrease From Other Tax Effects Tax Reconciliation

2021£-45.604
2022£-45.604
2023£20.881
2024—

Tax Tax Credit On Profit Or Loss On Ordinary Activities

2021£-183.137
2022£-183.137
2023£80.123
2024£141.779

Total Borrowings

2021£28.725.494
2022£28.725.494
2023£33.063.946
2024£36.063.946

Total Current Tax Expense Credit

2021—
2022—
2023—
2024£38.765

Total Deferred Tax Expense Credit

2021£-190.017
2022£-190.017
2023£87.003
2024£103.014
Métrica2021202220232024
Lucro / (prejuízo)£-190.017£-190.017£87.003£141.779
Outras receitas£1.628.440£1.628.440£3.652.957£3.913.386
Ativo total£2.998.849£2.998.849£7.099.235£6.090.534
Net Assets Liabilities£2.998.849£2.998.849£7.099.235£6.090.534
Equity£2.998.849£2.998.849£7.099.235£6.090.534
Current Assets£29.849.580£29.849.580£37.459.297£44.307.269
Net Current Assets Liabilities£29.217.422£29.217.422£34.227.342£37.089.265
Total Assets Less Current Liabilities£32.041.480£32.041.480£41.384.070£44.261.352
Debtors£29.849.580£29.849.580£37.459.297£44.307.269
Creditors£29.042.631£29.042.631£34.284.835£38.170.818
Other Creditors£166.941£166.941£0£37.600
Amounts Owed To Group Undertakings—£0£332.292£332.393
Investments Fixed Assets£2.824.058£2.824.058£7.156.728£7.172.087
Issue Equity Instruments—£2.824.058£4.185.418£900.000
Number Shares Issued Fully Paid96.30196.301417.617.629417.617.075
Par Value Share£0£0£0£0
Despesas administrativas£9.761£9.761——
Accrued Liabilities Deferred Income£317.137£317.137£1.220.889£2.106.872
Amounts Owed By Group Undertakings£29.659.563£29.659.563£37.356.283£44.307.269
Applicable Tax Rate£0£0£0£0
Audit Fees Expenses£2.000£2.000——
Comprehensive Income Expense—£174.791£-85.032£-1.024.060
Corporation Tax Payable£6.880£6.880£0£38.665
Current Tax For Period£6.880£6.880——
Deferred Tax Asset Debtors£190.017£190.017£103.014—
Deferred Tax Assets£190.017£190.017£103.014—
Deferred Tax Expense Credit Relating To Changes In Tax Rates Or Laws£-45.604£-45.604£20.881—
Deferred Tax Expense Credit Relating To Origination Reversal Timing Differences£-144.413£-144.413£66.122£103.014
Fixed Assets£2.824.058£2.824.058£7.156.728£7.172.087
Further Item Increase Decrease In Equity Component Total Income Expense Recognised Directly In Equity———£15.359
Income Expense Recognised Directly In Equity—£2.824.058£4.185.418£15.359
Increase Decrease In Current Tax From Adjustment For Prior Periods—£0£-6.880£38.765
Increase Decrease In Net Deferred Tax Liability From Amount Recognised In Profit Or Loss£-190.017£-190.017£87.003—
Interest Income From Group Undertakings£1.628.440£1.628.440£3.652.957£3.913.386
Interest Payable Similar Charges Finance Costs£1.627.025£1.627.025£3.657.866£4.795.667
Net Deferred Tax Liability Asset£-190.017£-190.017£-103.014—
Operating Profit Loss£-9.761£-9.761——
Other Interest Expense£1.627.025£1.627.025£3.657.866£4.795.667
Other Interest Receivable Similar Income Finance Income£1.628.440£1.628.440£3.652.957£3.913.386
Other Remaining Borrowings£28.725.494£28.725.494£4.338.452£3.000.000
Percentage Class Share Held In Subsidiary£1£1£1£1
Profit Loss On Ordinary Activities After Tax£174.791£174.791£-85.032£-1.024.060
Profit Loss On Ordinary Activities Before Tax£-8.346£-8.346£-4.909£-882.281
Tax Expense Credit Applicable Tax Rate£-1.586£-1.586£-933£-220.570
Tax Increase Decrease Arising From Group Relief Tax Reconciliation£-300.669£-300.669£-647.386£-978.347
Tax Increase Decrease From Effect Expenses Not Deductible For Tax Purposes Other Than Goodwill Amortisation Impairment£164.722£164.722£714.441£1.301.931
Tax Increase Decrease From Other Tax Effects Tax Reconciliation£-45.604£-45.604£20.881—
Tax Tax Credit On Profit Or Loss On Ordinary Activities£-183.137£-183.137£80.123£141.779
Total Borrowings£28.725.494£28.725.494£33.063.946£36.063.946
Total Current Tax Expense Credit———£38.765
Total Deferred Tax Expense Credit£-190.017£-190.017£87.003£103.014

Documentos

Confirmation statement

05/02/2026

Ver

Full accounts made up to 30 September 2024

27/06/2025

Ver

Change of director details

07/02/2025

Ver

Confirmation statement

06/02/2025

Ver

Change of details for relevant legal entity with significant control

01/10/2024

Ver

Change of director details

01/10/2024

Ver

Change of director details

01/10/2024

Ver

IA de documentos

Em breve

Companexia Document AI

Faça perguntas sobre entregas e extratos—a nossa IA lerá os documentos e responderá em contexto.

Annual Accounts

Contas do exercício que termina em: 30/09/2024

Arquivado: 30/09/2024

Ver

Full accounts made up to 30 September 2023

27/09/2024

Ver

Mostrando 1–10 de 39

1 / 4

Explorar mais empresas e pessoas

🇮🇪KILDALE LIMITED🇮🇪BRAMBURY LIMITED🇮🇪AVONMOUNT LIMITEDANAIS BEILIARD🇬🇧Mr Steven DugganOCTAVIA SMITH V
Lucro / (prejuízo) ano contra ano (2023 vs. 2024)Lucro / (prejuízo) ano contra ano
+63%
Rentabilidade dos ativos (líquida) (2024)Rentabilidade dos ativos (líquida)
2,3%
Rácio de capital próprio (2024)Rácio de capital próprio
100%
Ativos totais ano contra ano (2023 vs. 2024)Ativos totais ano contra ano
-14,2%
CAGR ativos totais (2021–2024)CAGR ativos totais
+26,6%

Saúde financeira

Rácios derivados das contas anuais. Os valores são omitidos quando faltam dados ou não são significativos.

Crescimento

Lucro / (prejuízo) ano contra ano (2022 vs. 2023)
+145,8%
Ativos totais ano contra ano (2022 vs. 2023)
+136,7%
Ativo circulante líquido ano contra ano (2022 vs. 2023)
+17,1%
Lucro / (prejuízo) ano contra ano (2023 vs. 2024)
+63%
Ativos totais ano contra ano (2023 vs. 2024)
-14,2%
  1. –
  2. –
  3. –BIOSCRIPT MIDCO 1 LIMITED
Ativo circulante líquido ano contra ano (2023 vs. 2024)
+8,4%
CAGR ativos totais (2021–2024)
+26,6%

Eficiência e rentabilidade

Rentabilidade dos ativos (líquida) (2021)
-6,3%
Rentabilidade dos ativos (líquida) (2022)
-6,3%
Rentabilidade dos ativos (líquida) (2023)
1,2%
Rentabilidade dos ativos (líquida) (2024)
2,3%

Capital circulante e liquidez

Ativo circulante líquido (2021)
£ 29.217.422
Ativo circulante líquido (2022)
£ 29.217.422
Ativo circulante líquido (2023)
£ 34.227.342
Ativo circulante líquido (2024)
£ 37.089.265

Estrutura de capital

Rácio de capital próprio (2021)
100%
Rácio de capital próprio (2022)
100%
Rácio de capital próprio (2023)
100%
Rácio de capital próprio (2024)
100%
Início
Reino Unido
Macclesfield